Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
May 31, 2019 5:45 am ET
Survival Benefit Now Observed with KEYTRUDA in Combination with Chemotherapy in All Patient Populations (Regardless of PD-L1 Expression) and with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 at CPS ≥1
Data Presented Today at 2019 ASCO Annual Meeting
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of the final analysis of the pivotal
Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck’s anti-PD-1
therapy, as monotherapy and in combination with chemotherapy, for the
first-line treatment of patients with recurrent or metastatic head and
neck squamous cell carcinoma (HNSCC) at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting (Abstract #6000). Data include
the first-time presentation of certain overall survival (OS) hypotheses
from the KEYTRUDA in combination with chemotherapy study arm based on
PD-L1 expression and the KEYTRUDA monotherapy study arm in the total
patient population. Results of an interim analysis were presented at the
European Society for Medical Oncology (ESMO) 2018 Congress and
demonstrated superior OS outcomes for KEYTRUDA in combination with
chemotherapy in the total population and KEYTRUDA monotherapy in
patients whose tumors expressed PD-L1 with Combined Positive Score (CPS)
≥20 and CPS ≥1 compared with the EXTREME regimen, the current standard
of care.
“It is exciting to see the full results from this trial, which is the
first study to show superior overall survival over the current standard
of care known as the EXTREME regimen,” said Dr. Danny Rischin, director
of the department of medical oncology, Peter MacCallum Cancer Centre,
Melbourne, Australia. “Patients with recurrent or metastatic head and
neck cancer have a poor prognosis with limited treatment options. These
findings underscore the potential of KEYTRUDA monotherapy and in
combination with platinum-based chemotherapy to become important new
treatment options.”
The new findings presented today from the final analysis showed that
KEYTRUDA in combination with chemotherapy (carboplatin or cisplatin plus
5-FU) reduced the risk of death by 40% in patients whose tumors
expressed PD-L1 with CPS≥20, demonstrating significantly longer OS (14.7
months [95% CI, 10.3-19.3]) compared with the EXTREME regimen (cetuximab
with carboplatin or cisplatin plus 5-fluorouracil [5-FU]), the current
standard of care (11.0 months [95% CI, 9.2-13.0]) (HR=0.60 [95% CI,
0.45-0.82]; p=0.0004). For the dual primary endpoint of progression-free
survival (PFS), statistical significance was not achieved for KEYTRUDA
in combination with chemotherapy in the CPS≥20 population compared with
the EXTREME regimen (HR=0.73 [95% CI, 0.55-.97]; p=0.0162). New findings
for the CPS ≥1 population showed KEYTRUDA in combination with
chemotherapy reduced the risk of death by 35% in these patients, with
significantly longer OS (13.6 months [95% CI, 10.7-15.5]) compared with
the EXTREME regimen (10.4 months [95% CI, 9.1-11.7]) (HR=0.65 [95% CI,
0.53-0.80]; p<0.0001). Per the sequential testing strategy, superiority
for PFS was not tested in this population (HR=0.82 [95% CI, 0.67-1.00]).
Results for OS with KEYTRUDA monotherapy in the total population were
consistent with the previously presented interim analysis, where
non-inferiority was demonstrated (HR=0.83 [95% CI, 0.70-0.99];
p=0.0199), with a median OS of 11.5 months (95% CI, 10.3-13.4) for
KEYTRUDA monotherapy in the total population compared with 10.7 months
(95% CI, 9.3-11.7) for the EXTREME regimen. There was no difference in
PFS between KEYTRUDA monotherapy in the total population and the EXTREME
regimen (HR=1.34 [95% CI, 1.13-1.59]).
“As a company, Merck is committed to advancing research in this
challenging treatment setting through our expansive head and neck cancer
clinical research program,” said Dr. Jonathan Cheng, vice president,
clinical research, Merck Research Laboratories. “The full data from
KEYNOTE-048 illustrate the impact of KEYTRUDA as monotherapy and in
combination with chemotherapy as potential new first-line treatment
options for patients with recurrent or metastatic head and neck squamous
cell carcinoma. We would like to sincerely thank the patients and
investigators for their involvement in KEYNOTE-048.”
As previously announced, the U.S. Food and Drug Administration (FDA) has
granted priority review for a new supplemental Biologics License
Application (sBLA) seeking approval for KEYTRUDA as monotherapy or in
combination with platinum and 5-FU chemotherapy for the first-line
treatment of patients with recurrent or metastatic HNSCC based in part
on data from the second interim analysis of KEYNOTE-048. The FDA has set
a Prescription Drug User Fee Act (PDUFA), or target action, date of June
10, 2019.
Study Design and Additional Data from KEYNOTE-048 (Abstract #6000)
KEYNOTE-048, a randomized, open-label Phase 3 trial (ClinicalTrials.gov,
NCT02358031), evaluated KEYTRUDA in combination with chemotherapy or
KEYTRUDA monotherapy, compared with the EXTREME regimen, as first-line
treatment in patients with recurrent or metastatic HNSCC. The dual
primary endpoints were OS and PFS. The secondary endpoints were PFS (at
six months and 12 months), objective response rate (ORR) and time to
deterioration in the Quality of Life Global Health Status/Quality of
Life Scales of the European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire and Safety. Duration of
response (DOR) was evaluated as part of a pre-specified exploratory
analysis. The primary and secondary endpoints, as well as exploratory
DOR analysis, were evaluated in patients whose tumors expressed PD-L1
(CPS ≥20 and CPS ≥1) and in the total population, based on a fixed
sequential testing strategy. Data cutoff for the final analysis was Feb.
25, 2019; data cutoff for the previously presented second interim
analysis was June 13, 2018. Details of the OS benefit observed at the
final analysis are below:
Summary of Overall Survival |
||||
Population (number of patients with event) | Final Analysis Hazard Ratio (95% CI) | |||
KEYTRUDA Monotherapy | ||||
PD-L1 CPS ≥20 (n=133) vs. EXTREME (n=122) | 0.58 (0.44-0.78)b | |||
PD-L1 CPS ≥1 (n=257) vs. EXTREME (n=255) | 0.74 (0.61-0.90)b | |||
Total Population (n=301) vs. EXTREME (n=300) | 0.83 (0.70-0.99); p=0.0199c | |||
KEYTRUDA in Combination with |
||||
PD-L1 CPS ≥20 (n=126) vs. EXTREME (n=110) | 0.60 (0.45–0.82); p=0.0004a | |||
PD-L1 CPS ≥1 (n=242) vs. EXTREME (n=235) | 0.65 (0.53–0.80); p<0.0001a | |||
Total Population (n=281) vs. EXTREME (n=278) | 0.72 (0.60-0.87)b |
a | Superiority demonstrated. | |
b |
No new statistical testing performed because population previously demonstrated superiority at interim analysis. |
|
c | Superiority not demonstrated. | |
The secondary endpoint of ORR was 42.9% for KEYTRUDA in combination with
chemotherapy in patients whose tumors expressed PD-L1 with CPS ≥20
compared with 38.2% for the EXTREME regimen. The ORR was 36.4% in
patients whose tumors expressed PD-L1 with CPS ≥1 for KEYTRUDA in
combination with chemotherapy compared with 35.7% for the EXTREME
regimen. The median DOR was 7.1 months (range, 2.1+ to 39.0+) for
KEYTRUDA in combination with chemotherapy in patients whose tumors
expressed PD-L1 with CPS ≥20 compared with 4.2 months (range, 1.2+ to
31.5+) for the EXTREME regimen. The median DOR was 6.7 months (range,
1.6+ to 39.0+) for KEYTRUDA in combination with chemotherapy in patients
whose tumors expressed PD-L1 with CPS ≥1 compared with 4.3 months
(range, 1.2+ to 31.5+) for the EXTREME regimen.
In the KEYTRUDA monotherapy arm, an analysis of the total patient
population showed an ORR of 16.9% compared with 36.0% for the EXTREME
regimen; the median DOR was 22.6 months (range, 1.5+ to 43.0+) compared
with 4.5 months (range, 1.2+ to 38.7+) for the EXTREME regimen.
As previously reported, there were no new safety concerns identified
with the use of KEYTRUDA in KEYNOTE-048. Grade 3-5 all-cause adverse
events occurred in 54.7%, 85.1% and 83.3% of patients in the KEYTRUDA
monotherapy, KEYTRUDA in combination with chemotherapy and EXTREME
regimen arms, respectively. Adverse events resulting in discontinuation
occurred in 12.0%, 32.6% and 27.5% of patients in the KEYTRUDA
monotherapy, KEYTRUDA in combination with chemotherapy and EXTREME
regimen arms, respectively. Treatment-related deaths occurred in 1.0%,
4.0% and 2.8% of patients in the KEYTRUDA monotherapy, KEYTRUDA in
combination with chemotherapy and EXTREME regimen arms, respectively.
Grade 3-5 immune-mediated or infusion reactions occurred in 7.0%, 5.4%
and 10.5% of patients in the KEYTRUDA monotherapy, KEYTRUDA in
combination with chemotherapy and EXTREME regimen arms, respectively.
Additional Information About KEYNOTE-048
KEYNOTE-048 enrolled 882 patients with recurrent or metastatic HNSCC who
were randomized to one of three regimens as first-line therapy, as
follows:
-
KEYTRUDA monotherapy (200 mg fixed dosed every three weeks [Q3W]) for
up to 24 months (n=301); or -
KEYTRUDA (200 mg fixed dose Q3W) in combination with cisplatin (100
mg/m2 IV Q3W) or carboplatin (AUC 5 IV Q3W) plus 5-FU (1000
mg/m2/day IV continuous from Day 1-4 Q3W (maximum six
cycles), followed by additional KEYTRUDA monotherapy maintenance
therapy until progression of disease, toxicity or until the patient
had received a maximum of 24 months total treatment (n=281); or -
EXTREME regimen including cetuximab at a loading dose (400 mg/m2
IV) followed by weekly doses (250 mg/m2 IV) in combination
with cisplatin (100 mg/m2 IV Q3W) or carboplatin (AUC 5 IV
Q3W) plus 5-FU (1000 mg/m2/day IV) continuous from Day 1-4
Q3W (maximum six cycles), followed by additional cetuximab monotherapy
maintenance therapy until progression of disease or toxicity (n=300).
About Head and Neck Cancer
Head and neck cancer describes a number of different tumors that develop
in or around the throat, larynx, nose, sinuses and mouth. Most head and
neck cancers are squamous cell carcinomas that begin in the flat,
squamous cells that make up the thin surface layer of the structures in
the head and neck. Two substances that greatly increase the risk of
developing head and neck cancer are tobacco and alcohol. It is estimated
that there were more than 887,000 new cases of head and neck cancer
diagnosed and over 453,000 deaths from the disease worldwide in 2018. In
the U.S. alone, it is estimated that there will be more than 65,000 new
cases of head and neck cancer diagnosed and over 14,000 deaths from the
disease in 2019.
About KEYTRUDA
®
(pembrolizumab) Injection,
100mg
KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of
the body’s immune system to help detect and fight tumor cells. KEYTRUDA
is a humanized monoclonal antibody that blocks the interaction between
PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes
which may affect both tumor cells and healthy cells.
Merck has the industry’s largest immuno-oncology clinical research
program. There are currently more than 1,000 trials studying KEYTRUDA
across a wide variety of cancers and treatment settings. The KEYTRUDA
clinical program seeks to understand the role of KEYTRUDA across cancers
and the factors that may predict a patient’s likelihood of benefitting
from treatment with KEYTRUDA, including exploring several different
biomarkers.
KEYTRUDA
®
(pembrolizumab) Indications and
Dosing
Melanoma
KEYTRUDA is indicated for the treatment of patients with unresectable or
metastatic melanoma. The recommended dose of KEYTRUDA in patients with
unresectable or metastatic melanoma is 200 mg administered as an
intravenous infusion over 30 minutes every three weeks until disease
progression or unacceptable toxicity.
KEYTRUDA is indicated for the adjuvant treatment of patients with
melanoma with involvement of lymph node(s) following complete resection.
The recommended dose of KEYTRUDA for the adjuvant treatment of adult
patients with melanoma is 200 mg administered as an intravenous infusion
over 30 minutes every three weeks until disease recurrence, unacceptable
toxicity, or for up to 12 months in patients without disease recurrence.
Lung Cancer
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is
indicated for the first-line treatment of patients with metastatic
nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK
genomic tumor aberrations.
KEYTRUDA, in combination with carboplatin and either paclitaxel or
paclitaxel protein-bound, is indicated for the first-line treatment of
patients with metastatic squamous NSCLC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment
of patients with stage III NSCLC who are not candidates for surgical
resection or definitive chemoradiation, or metastatic NSCLC, and whose
tumors express PD-L1 [tumor proportion score (TPS) ≥1%] as determined by
an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA, as a single agent, is indicated for the treatment of patients
with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined
by an FDA-approved test, with disease progression on or after
platinum-containing chemotherapy. Patients with EGFR or ALK genomic
tumor aberrations should have disease progression on FDA-approved
therapy for these aberrations prior to receiving KEYTRUDA.
In NSCLC, the recommended dose of KEYTRUDA is 200 mg administered as an
intravenous infusion over 30 minutes every three weeks until disease
progression, unacceptable toxicity, or up to 24 months in patients
without disease progression.
When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA
should be administered prior to chemotherapy when given on the same day.
See also the Prescribing Information for the chemotherapy agents
administered in combination with KEYTRUDA, as appropriate.
Head and Neck Cancer
KEYTRUDA is indicated for the treatment of patients with recurrent or
metastatic head and neck squamous cell carcinoma (HNSCC) with disease
progression on or after platinum-containing chemotherapy. This
indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA 200 mg
is administered as an intravenous infusion over 30 minutes every three
weeks until disease progression, unacceptable toxicity, or up to 24
months in patients without disease progression.
Classical Hodgkin Lymphoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients
with refractory classical Hodgkin lymphoma (cHL), or who have relapsed
after 3 or more prior lines of therapy. This indication is approved
under accelerated approval based on tumor response rate and durability
of response. Continued approval for this indication may be contingent
upon verification and description of clinical benefit in the
confirmatory trials. In adults with cHL, KEYTRUDA 200 mg is administered
as an intravenous infusion over 30 minutes every three weeks until
disease progression or unacceptable toxicity, or up to 24 months in
patients without disease progression. In pediatric patients with cHL,
KEYTRUDA is administered as an intravenous infusion over 30 minutes at a
dose of 2 mg/kg (up to a maximum of 200 mg) every three weeks until
disease progression or unacceptable toxicity, or up to 24 months in
patients without disease progression.
Primary Mediastinal Large B-Cell Lymphoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients
with refractory primary mediastinal large B-cell lymphoma (PMBCL), or
who have relapsed after 2 or more prior lines of therapy. This
indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials. KEYTRUDA is not recommended for
the treatment of patients with PMBCL who require urgent cytoreductive
therapy.
In adults with PMBCL, KEYTRUDA 200 mg is administered as an intravenous
infusion over 30 minutes every three weeks until disease progression,
unacceptable toxicity, or up to 24 months in patients without disease
progression. In pediatric patients with PMBCL, KEYTRUDA is administered
as an intravenous infusion over 30 minutes at a dose of 2 mg/kg (up to a
maximum of 200 mg) every three weeks until disease progression or
unacceptable toxicity, or up to 24 months in patients without disease
progression.
Urothelial Carcinoma
KEYTRUDA is indicated for the treatment of patients with locally
advanced or metastatic urothelial carcinoma (mUC) who are not eligible
for cisplatin-containing chemotherapy and whose tumors express PD-L1
[combined positive score (CPS) ≥10] as determined by an FDA-approved
test, or in patients who are not eligible for any platinum-containing
chemotherapy regardless of PD-L1 status. This indication is approved
under accelerated approval based on tumor response rate and duration of
response. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in the confirmatory
trials.
KEYTRUDA is indicated for the treatment of patients with locally
advanced or metastatic urothelial carcinoma (mUC) who have disease
progression during or following platinum-containing chemotherapy or
within 12 months of neoadjuvant or adjuvant treatment with
platinum-containing chemotherapy.
In locally advanced or metastatic urothelial carcinoma, KEYTRUDA 200 mg
is administered as an intravenous infusion over 30 minutes every three
weeks until disease progression or unacceptable toxicity, or up to 24
months in patients without disease progression.
Microsatellite Instability-High (MSI-H) Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients
with unresectable or metastatic microsatellite instability-high (MSI-H)
or mismatch repair deficient (dMMR)
-
solid tumors that have progressed following prior treatment and who
have no satisfactory alternative treatment options, or -
colorectal cancer that has progressed following treatment with
fluoropyrimidine, oxaliplatin, and irinotecan.
This indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in the confirmatory trials. The safety and
effectiveness of KEYTRUDA in pediatric patients with MSI-H central
nervous system cancers have not been established.
In adult patients with MSI-H cancer, KEYTRUDA 200 mg is administered as
an intravenous infusion over 30 minutes every three weeks until disease
progression, unacceptable toxicity, or up to 24 months in patients
without disease progression. In pediatric patients with MSI-H cancer,
KEYTRUDA is administered as an intravenous infusion over 30 minutes at a
dose of 2 mg/kg (up to a maximum of 200 mg) every three weeks until
disease progression or unacceptable toxicity, or up to 24 months in
patients without disease progression.
Gastric Cancer
KEYTRUDA is indicated for the treatment of patients with recurrent
locally advanced or metastatic gastric or gastroesophageal junction
(GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined
by an FDA-approved test, with disease progression on or after two or
more prior lines of therapy including fluoropyrimidine- and
platinum-containing chemotherapy and if appropriate, HER2/neu-targeted
therapy. This indication is approved under accelerated approval based on
tumor response rate and durability of response. Continued approval for
this indication may be contingent upon verification and description of
clinical benefit in the confirmatory trials. The recommended dose of
KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every
three weeks until disease progression, unacceptable toxicity, or up to
24 months in patients without disease progression.
Cervical Cancer
KEYTRUDA is indicated for the treatment of patients with recurrent or
metastatic cervical cancer with disease progression on or after
chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an
FDA-approved test. This indication is approved under accelerated
approval based on tumor response rate and durability of response.
Continued approval for this indication may be contingent upon
verification and description of clinical benefit in the confirmatory
trials. The recommended dose of KEYTRUDA is 200 mg as an intravenous
infusion over 30 minutes every three weeks until disease progression,
unacceptable toxicity or up to 24 months in patients without disease
progression.
Hepatocellular Carcinoma
KEYTRUDA is indicated for the treatment of patients with hepatocellular
carcinoma (HCC) who have been previously treated with sorafenib. This
indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in the confirmatory trials. The recommended dose of
KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every
three weeks until disease progression, unacceptable toxicity, or up to
24 months in patients without disease progression.
Merkel Cell Carcinoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients
with recurrent locally advanced or metastatic Merkel cell carcinoma.
This indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in the confirmatory trials. The recommended dose of
KEYTRUDA in adults is 200 mg administered as an intravenous infusion
over 30 minutes every three weeks until disease progression,
unacceptable toxicity, or up to 24 months in patients without disease
progression. The recommended dose of KEYTRUDA in pediatric patients is 2
mg/kg (up to a maximum of 200 mg), administered as an intravenous
infusion over 30 minutes every three weeks until disease progression or
unacceptable toxicity, or up to 24 months in patients without disease
progression.
Renal Cell Carcinoma
KEYTRUDA, in combination with axitinib, is indicated for the first-line
treatment of patients with advanced renal cell carcinoma. In renal cell
carcinoma, KEYTRUDA 200 mg is administered as an intravenous infusion
over 30 minutes every 3 weeks in combination with 5 mg axitinib orally
twice daily until disease progression, unacceptable toxicity, or for
KEYTRUDA, up to 24 months in patients without disease progression. When
axitinib is used in combination with KEYTRUDA, dose escalation of
axitinib above the initial 5 mg dose may be considered at intervals of
six weeks or longer. See also the Prescribing Information for
recommended axitinib dosing information.
Selected Important Safety Information for KEYTRUDA (pembrolizumab)
Injection, 100mg
Immune-Mediated Pneumonitis
KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.
Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers
receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4
(0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC
patients receiving KEYTRUDA as a single agent, including Grades 3-4 in
3.2% of patients, and occurred more frequently in patients with a
history of prior thoracic radiation (17%) compared to those without
(7.7%).
Monitor patients for signs and symptoms of pneumonitis. Evaluate
suspected pneumonitis with radiographic imaging. Administer
corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA
for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or
recurrent Grade 2 pneumonitis.
Immune-Mediated Colitis
KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%
(48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3
(1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of
colitis. Administer corticosteroids for Grade 2 or greater colitis.
Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for
Grade 4 colitis.
Immune-Mediated Hepatitis, or Hepatoxicity (in Combination With
Axitinib)
Immune-Mediated Hepatitis
KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%
(19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3
(0.4%), and 4 (<0.1%). Monitor patients for changes in liver function.
Administer corticosteroids for Grade 2 or greater hepatitis and, based
on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.
Hepatotoxicity (in Combination With Axitinib)
KEYTRUDA in combination with axitinib can cause hepatic toxicity with
higher than expected frequencies of Grades 3 and 4 ALT and AST
elevations compared to KEYTRUDA alone. Grades 3 and 4 increased ALT and
AST were seen in 20% and 13% of patients, respectively. Monitor liver
enzymes before initiation of and periodically throughout treatment.
Consider more frequent monitoring of liver enzymes as compared to when
the drugs are used in monotherapy. For elevated liver enzymes, interrupt
KEYTRUDA and axitinib, and consider administering corticosteroids as
needed.
Immune-Mediated Endocrinopathies
KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes
mellitus. Hypophysitis occurred in 0.6% (17/2799) of patients, including
Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5%
(237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The
incidence of new or worsening hypothyroidism was higher in patients with
HNSCC, occurring in 15% (28/192) of patients. Hyperthyroidism occurred
in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),
and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade
2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,
occurred in 0.2% (6/2799) of patients.
Monitor patients for signs and symptoms of hypophysitis (including
hypopituitarism and adrenal insufficiency), thyroid function (prior to
and periodically during treatment), and hyperglycemia. For hypophysitis,
administer corticosteroids and hormone replacement as clinically
indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for
Grade 3 or 4 hypophysitis. Administer hormone replacement for
hypothyroidism and manage hyperthyroidism with thionamides and
beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade
3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes and
withhold KEYTRUDA and administer antihyperglycemics in patients with
severe hyperglycemia.
Immune-Mediated Nephritis and Renal Dysfunction
KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%
(9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3
(0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of
patients receiving KEYTRUDA in combination with pemetrexed and platinum
chemotherapy. Monitor patients for changes in renal function. Administer
corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for
Grade 2; permanently discontinue for Grade 3 or 4 nephritis.
Immune-Mediated Skin Reactions
Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative
dermatitis, and bullous pemphigoid, can occur. Monitor patients for
suspected severe skin reactions and based on the severity of the adverse
reaction, withhold or permanently discontinue KEYTRUDA and administer
corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA
and refer the patient for specialized care for assessment and treatment.
If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.
Other Immune-Mediated Adverse Reactions
Immune-mediated adverse reactions, which may be severe or fatal, can
occur in any organ system or tissue in patients receiving KEYTRUDA and
may also occur after discontinuation of treatment. For suspected
immune-mediated adverse reactions, ensure adequate evaluation to confirm
etiology or exclude other causes. Based on the severity of the adverse
reaction, withhold KEYTRUDA and administer corticosteroids. Upon
improvement to Grade 1 or less, initiate corticosteroid taper and
continue to taper over at least 1 month. Based on limited data from
clinical studies in patients whose immune-related adverse reactions
could not be controlled with corticosteroid use, administration of other
systemic immunosuppressants can be considered. Resume KEYTRUDA when the
adverse reaction remains at Grade 1 or less following corticosteroid
taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated
adverse reaction that recurs and for any life-threatening
immune-mediated adverse reaction.
The following clinically significant immune-mediated adverse reactions
occurred in less than 1% (unless otherwise indicated) of 2799 patients:
arthritis (1.5%), uveitis, myositis, Guillain-Barré syndrome, myasthenia
gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and
encephalitis. In addition, myelitis and myocarditis were reported in
other clinical trials, including classical Hodgkin lymphoma, and
postmarketing use.
Treatment with KEYTRUDA may increase the risk of rejection in solid
organ transplant recipients. Consider the benefit of treatment vs the
risk of possible organ rejection in these patients.
Infusion-Related Reactions
KEYTRUDA can cause severe or life-threatening infusion-related
reactions, including hypersensitivity and anaphylaxis, which have been
reported in 0.2% (6/2799) of patients. Monitor patients for signs and
symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop
infusion and permanently discontinue KEYTRUDA.
Complications of Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT)
Immune-mediated complications, including fatal events, occurred in
patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of
23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6
(26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2
(9%) developed severe hepatic veno-occlusive disease (VOD) after
reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute
GVHD after allogeneic HSCT have also been reported in patients with
lymphoma who received a PD-1 receptor–blocking antibody before
transplantation. Follow patients closely for early evidence of
transplant-related complications such as hyperacute graft-versus-host
disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile
syndrome, hepatic veno-occlusive disease (VOD), and other
immune-mediated adverse reactions.
In patients with a history of allogeneic HSCT, acute GVHD (including
fatal GVHD) has been reported after treatment with KEYTRUDA. Patients
who experienced GVHD after their transplant procedure may be at
increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA
vs the risk of GVHD in these patients.
Increased Mortality in Patients With Multiple Myeloma
In trials in patients with multiple myeloma, the addition of KEYTRUDA to
a thalidomide analogue plus dexamethasone resulted in increased
mortality. Treatment of these patients with a PD-1 or PD-L1 blocking
antibody in this combination is not recommended outside of controlled
trials.
Embryofetal Toxicity
Based on its mechanism of action, KEYTRUDA can cause fetal harm when
administered to a pregnant woman. Advise women of this potential risk.
In females of reproductive potential, verify pregnancy status prior to
initiating KEYTRUDA and advise them to use effective contraception
during treatment and for 4 months after the last dose.
Adverse Reactions
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%
of 555 patients with advanced melanoma; adverse reactions leading to
permanent discontinuation in more than one patient were colitis (1.4%),
autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy
(0.4%), and cardiac failure (0.4%). The most common adverse reactions
(≥20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and
nausea (21%).
In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse
reactions in 14% of 509 patients; the most common (≥1%) were pneumonitis
(1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions
occurred in 25% of patients receiving KEYTRUDA. The most common adverse
reaction (≥20%) with KEYTRUDA was diarrhea (28%).
In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and
platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was
discontinued due to adverse reactions in 20% of 405 patients. The most
common adverse reactions resulting in permanent discontinuation of
KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most
common adverse reactions (≥20%) with KEYTRUDA were nausea (56%), fatigue
(56%), constipation (35%), diarrhea (31%), decreased appetite (28%),
rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia
(20%).
In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and
either paclitaxel or paclitaxel protein-bound in metastatic squamous
NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101
patients. The most frequent serious adverse reactions reported in at
least 2% of patients were febrile neutropenia, pneumonia, and urinary
tract infection. Adverse reactions observed in KEYNOTE-407 were similar
to those observed in KEYNOTE-189 with the exception that increased
incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs
25%) were observed in the KEYTRUDA and chemotherapy arm compared to the
placebo and chemotherapy arm in KEYNOTE-407.
In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in
19% of 636 patients; the most common were pneumonitis (3%), death due to
unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious
adverse reactions reported in at least 2% of patients were pneumonia
(7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural
effusion (2.2%). The most common adverse reaction (≥20%) was fatigue
(25%).
In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse
reactions in 8% of 682 patients with metastatic NSCLC; the most common
was pneumonitis (1.8%). The most common adverse reactions (≥20%) were
decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).
In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in
17% of 192 patients with HNSCC. Serious adverse reactions occurred in
45% of patients. The most frequent serious adverse reactions reported in
at least 2% of patients were pneumonia, dyspnea, confusional state,
vomiting, pleural effusion, and respiratory failure. The most common
adverse reactions (≥20%) were fatigue, decreased appetite, and dyspnea.
Adverse reactions occurring in patients with HNSCC were generally
similar to those occurring in patients with melanoma or NSCLC who
received KEYTRUDA as a monotherapy, with the exception of increased
incidences of facial edema and new or worsening hypothyroidism.
In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%
of 210 patients with cHL. Serious adverse reactions occurred in 16% of
patients; those ≥1% included pneumonia, pneumonitis, pyrexia, dyspnea,
GVHD, and herpes zoster. Two patients died from causes other than
disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1
from septic shock. The most common adverse reactions (≥20%) were fatigue
(26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea
(20%), and rash (20%).
In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%
of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of
patients and included arrhythmia (4%), cardiac tamponade (2%),
myocardial infarction (2%), pericardial effusion (2%), and pericarditis
(2%). Six (11%) patients died within 30 days of start of treatment. The
most common adverse reactions (≥20%) were musculoskeletal pain (30%),
upper respiratory tract infection and pyrexia (28% each), cough (26%),
fatigue (23%), and dyspnea (21%).
In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in
11% of 370 patients with locally advanced or metastatic urothelial
carcinoma. Serious adverse reactions occurred in 42% of patients; those
≥2% were urinary tract infection, hematuria, acute kidney injury,
pneumonia, and urosepsis. The most common adverse reactions (≥20%) were
fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),
constipation (21%), rash (21%), and diarrhea (20%).
In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%
of 266 patients with locally advanced or metastatic urothelial
carcinoma. The most common adverse reaction resulting in permanent
discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse
reactions occurred in 39% of KEYTRUDA-treated patients; those ≥2% were
urinary tract infection, pneumonia, anemia, and pneumonitis. The most
common adverse reactions (≥20%) in patients who received KEYTRUDA were
fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased
appetite (21%), nausea (21%), and rash (20%).
Adverse reactions occurring in patients with gastric cancer were similar
to those occurring in patients with melanoma or NSCLC who received
KEYTRUDA as a monotherapy.
In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%
of 98 patients with recurrent or metastatic cervical cancer. Serious
adverse reactions occurred in 39% of patients receiving KEYTRUDA; the
most frequent included anemia (7%), fistula, hemorrhage, and infections
[except urinary tract infections] (4.1% each). The most common adverse
reactions (≥20%) were fatigue (43%), musculoskeletal pain (27%),
diarrhea (23%), pain and abdominal pain (22% each), and decreased
appetite (21%).
Adverse reactions occurring in patients with HCC were generally similar
to those in patients with melanoma or NSCLC who received KEYTRUDA as a
monotherapy, with the exception of increased incidences of ascites (8%
Grades 3-4) and immune-mediated hepatitis (2.9%). Laboratory
abnormalities (Grades 3-4) that occurred at a higher incidence were
elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).
Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse
reactions occurring in patients with MCC were generally similar to those
occurring in patients with melanoma or NSCLC who received KEYTRUDA as a
monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a
higher incidence were elevated AST (11%) and hyperglycemia (19%).
KEYNOTE-426, when KEYTRUDA was administered in combination with
axitinib, fatal adverse reactions occurred in 3.3% of 429 patients.
Serious adverse reactions occurred in 40% of patients, the most frequent
of which (≥1%) included hepatotoxicity (7%), diarrhea (4.2%), acute
kidney injury (2.3%), dehydration (1%), and pneumonitis (1%).
Permanent discontinuation due to an adverse reaction occurred in 31% of
patients; KEYTRUDA only (13%), axitinib only (13%), and the combination
(8%). The most common adverse reactions (>1%) resulting in permanent
discontinuation of KEYTRUDA, axitinib, or the combination were
hepatotoxicity (13%), diarrhea/colitis (1.9%), acute kidney injury
(1.6%), and cerebrovascular accident (1.2%).
When KEYTRUDA was used in combination with axitinib, the most common
adverse reactions (≥20%) were diarrhea (56%), fatigue/asthenia (52%),
hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%),
decreased appetite (30%), palmar-plantar erythrodysesthesia (28%),
nausea (28%), stomatitis/mucosal inflammation (27%), dysphonia (25%),
rash (25%), cough (21%), and constipation (21%).
Lactation
Because of the potential for serious adverse reactions in breastfed
children, advise women not to breastfeed during treatment and for 4
months after the final dose.
Pediatric Use
There is limited experience in pediatric patients. In a trial, 40
pediatric patients (16 children aged 2 years to younger than 12 years
and 24 adolescents aged 12 years to 18 years) with various cancers,
including unapproved usages, were administered KEYTRUDA 2 mg/kg every 3
weeks. Patients received KEYTRUDA for a median of 3 doses (range 1–17
doses), with 34 patients (85%) receiving 2 doses or more. The safety
profile in these pediatric patients was similar to that seen in adults;
adverse reactions that occurred at a higher rate (≥15% difference) in
these patients when compared to adults under 65 years of age were
fatigue (45%), vomiting (38%), abdominal pain (28%), increased
transaminases (28%), and hyponatremia (18%).
Merck’s Focus on Cancer
Our goal is to translate breakthrough science into innovative oncology
medicines to help people with cancer worldwide. At Merck, the potential
to bring new hope to people with cancer drives our purpose and
supporting accessibility to our cancer medicines is our commitment. As
part of our focus on cancer, Merck is committed to exploring the
potential of immuno-oncology with one of the largest development
programs in the industry across more than 30 tumor types. We also
continue to strengthen our portfolio through strategic acquisitions and
are prioritizing the development of several promising oncology
candidates with the potential to improve the treatment of advanced
cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
About Merck
For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect
with us on Twitter,
Facebook,
Instagram,
YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. There can be no guarantees with
respect to pipeline products that the products will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2018 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov
).
Please see Prescribing Information for KEYTRUDA at
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
and Medication Guide for KEYTRUDA at
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf
.
Media:
Pamela Eisele
(267) 305-3558
or
Ayn Wisler
(908) 740-5590
Investors:
Teri Loxam
(908) 740-1986
or
Peter Dannenbaum
(908) 740-1037